MedMira Inc.
155 Chain Lake Drive
Halifax
Nova Scotia
B3S 1B3
Canada
Tel: 902-450-1588
Fax: 902-450-1580
Website: http://www.medmira.com/
Email: ir@medmira.com
129 articles about MedMira Inc.
-
MedMira receives CE mark for Multiplo® Complete Syphilis (TP/nTP) Antibody Test
5/12/2022
Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the achievement of another milestone in its regulatory strategy by receiving the CE mark for its Multiplo® Complete Syphilis (TP/nTP) Antibody Test (Multiplo® TP/nTP).
-
MedMira Reports Second Quarter Results FY2022
4/1/2022
MedMira Inc., reported on its financial results for the quarter ended January 31, 2022.
-
MedMira receives the CE mark for its Reveal® TP (Syphilis) and starts clinical trials in Canada
3/9/2022
Today, MedMira Inc. (MedMira) (TSXV: MIR) launches its Reveal® TP (Syphilis) product in Europe and gets clinical trials underway in Canada.
-
MedMira Receives CE Marking for its REVEALCOVID-19® PLUS Total Antibody Test
2/9/2022
Today, MedMira Inc. (MedMira) (TSXV: MIR) has received the CE mark for its REVEALCOVID-19® PLUS Total Antibody Test.
-
MedMira Provides a Pre-Annual General Meeting Update
2/4/2022
Today, MedMira Inc. (MedMira) (TSXV: MIR) provides a pre-Annual General Meeting (AGM) update on its regulatory and product development progress.
-
MedMira Reports First Quarter Results FY2022
12/31/2021
MedMira Inc., reported on its financial results for the quarter ended October 31, 2021.
-
MedMira Announces VYRA™ CoV2Flu and Additional Regulatory Opportunities
12/22/2021
MedMira Inc. announces the expansion of its VYRA™ product line by launching its VYRA™ CoV2Flu Rapid Antigen Rapid Test.
-
MedMira strengthen its Board with New Appointment
12/17/2021
MedMira Inc. announced today the appointment of Mr. Thomas Bergmann to the board effective immediately.
-
MedMira announces significant debt reduction and additional growth capital
12/15/2021
MedMira Inc. announces a financial package of over $5.23 million to support the Company’s FY2022 corporate strategy by its largest shareholder and related parties.
-
MedMira Reports FY2021 Fourth Quarter and Year End Financial Results
12/1/2021
MedMira Inc., reported on its financial results for the financial year ended July 31, 2021.
-
MedMira Reports Third Quarter Results FY2021
6/29/2021
MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the quarter ended April 30, 2021.
-
Performance Update on World Health Organisation SARS-CoV2 Serology Standards
6/15/2021
MedMira Inc. announces the World Health Organization SARS-CoV-2 serology standards testing results.
-
MedMira Reports Second Quarter Results FY2021
4/1/2021
MedMira Inc., reported on its financial results for the quarter ended January 31, 2021.
-
Product and Regulatory Update on MedMira’s COVID-19 Product Family
3/3/2021
MedMira Inc. announces the expansion of its product portfolio and outlines the company’s COVID-19 market and regulatory plan.
-
Progress Update on MedMira’s COVID-19 Product Family
1/30/2021
Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the development of a rapid antibody test prototype that detects the presence of the neutralizing antibodies against the SARS-CoV-2 virus.
-
MedMira Announces Product Update
12/30/2020
Today, MedMira Inc. (MedMira) (TSXV: MIR), is pleased to announce its validated REVEALCOVID-19TM PLUS Total Antibody Test for the detection of total antibodies against both the Nucleocapsid and Spike regions of the SARS-CoV-2. REVEALCOVID-19TM PLUS Total Antibody Test
-
MedMira Reports First Quarter Results FY2021
12/25/2020
MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the quarter ended October 31, 2020. Profit and Loss Highlights Revenue: The Company recorded revenues in Q1 FY2021 of $1,602,823 compared to $89,132 in Q1 FY2020. The increase in revenue was due to the Company’s revenues generated from sales of the REVEALCOVID-19 TM Total Antibody Test and associated products and services. Gross Profit: The Company rec
-
MedMira Reports FY2020 Fourth Quarter and Year End Financial Results
12/1/2020
MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the financial year ended July 31, 2019.
-
MedMira reports additional independent performance evaluation results of REVEALCOVID-19™ Total Antibody Test
10/7/2020
Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the results of the latest independent performance evaluation results of REVEALCOVID-19™ Total Antibody Test.
-
REVEALCOVID-19™ Total Antibody Test Sensitivity and Cross-Reactivity Analysis
9/3/2020
MedMira Inc. reports findings to further emphasize the high sensitivity of REVEALCOVID-19™ Total Antibody Test 7 days post symptom onset as well as highlights the test’s zero cross-reactivity with HIV positive samples.